Sunesis Pharmaceuticals Inc - Current report filing (8-K)
March 11 2008 - 5:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington
,
D.C.20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported):
March 5,
2008
SUNESIS
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-51531
|
|
94-3295878
|
|
(State
or other jurisdiction
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
of
incorporation)
|
|
|
|
|
|
|
|
|
|
|
|
341
Oyster Point
Boulevard
|
|
|
|
South
San Francisco, California
|
|
94080
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(650)
266-3500
(Former
name or former address, if changed since last report.)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
Written communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On
March
5, 2008, the Board of Directors (the “Board”) of Sunesis Pharmaceuticals, Inc.
(the “Company”) approved its 2008 Bonus Program (the “2008 Bonus Program”). The
2008 Bonus Program provides for the award of cash bonuses to our executive
officers and other eligible employees for performance in 2008 based on
the level
of achievement by the Company of certain corporate objectives and, in
case of
each participant, based on such participant’s level of achievement of certain
individual performance objectives as set by the Company
’s
Compensation
Committee (and, in the case of the Company’s Chief Executive Officer and
Executive Chairman, as set by the Board). A copy of the 2008 Bonus Program
is attached hereto as Exhibit 10.55 and incorporated herein by reference.
The
target bonus levels described therein and the process for determining
awards
remains unchanged from 2007.
Item
9.01 Financial Statements and Exhibits.
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
10.55*
|
|
Sunesis
Pharmaceuticals, Inc. 2008 Bonus
Program.
|
*
Management contract or compensatory plan.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
SUNESIS
PHARMACEUTICALS, INC.
|
|
|
|
|
|
Dated:
March 11, 2008
|
|
|
|
|
|
By:
|
/s/
Valerie L. Pierce
|
|
|
|
|
|
Valerie
L. Pierce
|
|
|
|
|
Senior
Vice President, General Counsel and Corporate
Secretary
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
10.55*
|
|
Sunesis
Pharmaceuticals, Inc. 2008 Bonus
Program.
|
_______________________________
*
Management contract or compensatory plan.
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024
